Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	43.29	37.07	11.81	33.51	25.18
Short-Term Investments	31.51	15.36	14.86	-	-
Cash & Short-Term Investments	74.8	52.43	26.67	33.51	25.18
Cash Growth	37.58%	96.56%	-20.41%	33.10%	-
Accounts Receivable	27.76	31.08	19.59	15.16	15.61
Other Receivables	0.26	0.23	5.19	1.29	-
Receivables	28.25	36.95	29.15	16.84	17.14
Inventory	11.43	10.17	6.34	4.28	6.12
Prepaid Expenses	7.6	1.34	1.19	1.55	0.38
Other Current Assets	-	1.49	1.44	1.05	0.84
Total Current Assets	122.07	102.37	64.79	57.22	49.65
Property, Plant & Equipment	30.56	24.73	25.7	23.78	18.38
Long-Term Investments	30.24	25.12	26.17	23.43	7.39
Other Intangible Assets	4.53	6.15	1.71	1.7	1.86
Long-Term Deferred Tax Assets	9.28	6.87	5.62	4.7	4.08
Other Long-Term Assets	2.57	0.89	1.43	5.72	3.39
Total Assets	199.26	166.13	125.41	116.54	84.75

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Accounts Payable	1.24	0.12	0.11	0.36	0.12
Accrued Expenses	16.08	12.09	9.3	10.56	6.77
Current Portion of Leases	1.39	0.64	0.71	0.21	0.49
Current Income Taxes Payable	2.15	2.94	2.83	5.05	2.1
Current Unearned Revenue	0.21	0.11	0.16	0.08	0.17
Other Current Liabilities	7.6	2.39	6.41	3.79	2.59
Total Current Liabilities	28.66	18.29	19.52	20.05	12.24
Long-Term Leases	2.03	0.3	0.89	0.2	0.12
Long-Term Unearned Revenue	0.83	0.85	0.93	0.21	0.12
Other Long-Term Liabilities	2.81	4.41	5.68	17.61	0.06
Total Liabilities	34.34	23.85	27	38.07	12.54

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Common Stock	0.11	0.09	0.09	0.08	0.06
Additional Paid-In Capital	240.64	172.05	136.19	68.18	32.8
Retained Earnings	-134.31	-65.33	-70.36	-82.44	10.06
Comprehensive Income & Other	1.49	-0.78	-2.6	-1.64	-0.39
Total Common Equity	107.93	106.03	63.32	-15.83	42.52
Minority Interest	34.56	36.25	35.08	29.78	29.7
Shareholders' Equity	164.92	142.28	98.4	78.47	72.22
Total Liabilities & Equity	199.26	166.13	125.41	116.54	84.75

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Total Debt	3.42	0.94	1.6	0.41	0.61
Net Cash (Debt)	71.38	51.49	25.07	33.1	24.56
Net Cash Growth	34.75%	105.34%	-24.25%	34.76%	-
Net Cash Per Share	0.76	0.50	0.25	0.50	0.32
Filing Date Shares Outstanding	106.03	91.31	93.61	85.42	63.59
Total Common Shares Outstanding	106.03	91.31	86.31	76.6	63.59
Working Capital	93.41	84.08	45.27	37.17	37.41
Book Value Per Share	1.02	1.16	0.73	-0.21	0.67
Tangible Book Value	103.4	99.88	61.61	-17.53	40.67
Tangible Book Value Per Share	0.98	1.09	0.71	-0.23	0.64
Buildings	20.3	19.57	18.98	12.29	10.84
Machinery	16.77	10.84	10.28	7.39	5.69
Construction In Progress	0.57	0.77	0.22	7.88	4.85
Leasehold Improvements	2.35	-	-	-	0.33

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 30, 2026

Data Sources Report a data error